Valion Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Valion Bio, Inc. (VBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 938 shares for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2024-03-25
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2022-12-31 was -92.81K shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2022-09-30 was 0.00 shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 938.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | -92.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -92.81K shares derived: sum of 2 quarters · filed 2024-03-25 | 938.00 shares 10-K · filed 2024-03-25 | 93.75K shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 93.75K shares 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 93.75K shares 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |